Please ensure Javascript is enabled for purposes of website accessibility

Nasdaq Soars Nearly 300 Points as Intra-Cellular Breaks Through; a Lemon for Lululemon?

By Dan Caplinger – Sep 9, 2020 at 5:12PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A nice bounce for the market was overdue.

After three days of steep declines, on Wednesday the Nasdaq Composite (^IXIC 0.00%) managed to recover some lost ground. Investors were ready for a bounce, and that's what they got. Some hard-hit tech stocks put together big gains, and collectively, they carried the Nasdaq to a rise of nearly 300 points.

The big winner on the Nasdaq was Intra-Cellular Therapies (ITCI -4.81%), which had groundbreaking news in an area of the biopharmaceutical industry that had nothing to do with COVID-19 treatment. Meanwhile, shares of lululemon athletica (LULU -4.28%) have soared in 2020, but it wasn't able to join the celebration after announcing quarterly results that raised some questions about the coming holiday season.

Rising stock charts superimposed over digital map of the world

Image source: Getty Images.

A big win in the fight against bipolar disorder

Shares of Intra-Cellular Therapies skyrocketed 73% on Wednesday. The biotech announced some trial results that encouraged shareholders about the prospects for a promising treatment.

Intra-Cellular released results from its study of lumateperone in treating patients with bipolar depression. The candidate drug met its primary endpoint of improvement on a commonly used depression rating scale compared to placebo, as well as secondary endpoints and safety profiles.

The company had previously reported positive results from another phase 3 study that used lumateperone exclusively. The study announced today used the treatment in conjunction with other mood stabilizing treatments like lithium or valproate.

Intra-Cellular immediately took advantage of the rise, announcing a $350 million secondary stock offering after the market closed Wednesday afternoon. Yet even that news didn't immediately bring a big reversal to the gains. That shows how excited investors are about the prospects for lumateperone to help patients with bipolar disorders.

A yoga retail letdown

On the down side, shares of Lululemon lost 7%. The yoga apparel retail specialist announced its second-quarter financial results late Tuesday, and although there were a lot of good things in its report, shareholders weren't ready to deal with some concerns about the future.

Lululemon held up well during a tough environment for retail generally. Revenue rose 2% during the period compared to the previous year's quarter. Revenue from retail stores dropped by more than half, reflecting closures throughout much of Q2 because of the COVID-19 pandemic. Yet direct-to-consumer sales made up the difference, soaring 155% year over year.

However, Lululemon didn't emerge unscathed. Although earnings were better than expected, they were still down by nearly a third from year-earlier levels. Moreover, the company expects that expenses are likely to keep rising in the remainder of the year. Higher marketing costs in particular could weigh on the bottom line.

Retail stocks have suffered a lot, but the drop for Lululemon still leaves the share price at more than double its lowest levels in March. Long-term investors don't need to panic about the yoga retailer's prospects for the foreseeable future.

Dan Caplinger has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Lululemon Athletica. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Lululemon Athletica Inc. Stock Quote
Lululemon Athletica Inc.
$293.20 (-4.28%) $-13.10
Intra-Cellular Therapies, Inc. Stock Quote
Intra-Cellular Therapies, Inc.
$43.51 (-4.81%) $-2.20
NASDAQ Composite Index (Price Return) Stock Quote
NASDAQ Composite Index (Price Return)
$11,066.81 (0.00%) $0.00

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/25/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.